持续缓解类风湿关节炎中DMARD减量策略的疗效与安全性比较:系统综述与网络Meta分析
结果显示,与持续治疗相比,减量总体增加复发风险(RR 1.94;95%CI 1.30-2.89);在减量策略中,bDMARD减量而继续cDMARD(N4)的复发风险最接近持续治疗(RR 1.17;95%CI 0.76-1.82),而停用bDMARD继续cDMARD(N3)显著增加复发风险(RR 3.06;95%CI 1.81-5.16)。
要点
- 持续缓解RA患者减量DMARD总体增加复发风险(RR 1.94)。
- bDMARD减量而继续cDMARD的复发风险最接近持续治疗。
- 停用bDMARD而继续cDMARD显著增加复发风险。
核心结论
- 在持续缓解的RA患者中,逐步减少bDMARD剂量并以cDMARD为背景治疗显示出最有利的复发风险比较特征。
- 停用bDMARD与显著更高的复发风险相关。
主要发现
- 与持续治疗相比,减量DMARD总体增加复发风险(RR 1.94;95%CI 1.30-2.89)。
- bDMARD减量而继续cDMARD(N4)的复发风险最接近持续治疗(RR 1.17;95%CI 0.76-1.82)。
- 停用bDMARD而继续cDMARD(N3)相比持续治疗增加复发风险(RR 3.06;95%CI 1.81-5.16),相比N4亦增加(RR 2.61;95%CI 1.44-4.72)。
- 策略排序为N0 > N4 > N1 > N3。
- CINeMA置信度:N3 vs N0为高,N4 vs N0为中等。
关键数值与推荐
- 主要网络比较维持治疗(N0)、cDMARD与bDMARD同时减量(N1)、停用bDMARD继续cDMARD(N3)、bDMARD减量继续cDMARD(N4)。
- 复发风险以RR(95%CI)汇总,采用一致性模型并以P评分排序。
临床怎么用
- 对于持续缓解的RA患者,优先考虑bDMARD减量而保留cDMARD作为背景治疗,而非直接停用bDMARD。
- 减量决策需权衡复发风险,停用bDMARD与显著更高的复发风险相关。
局限性
- 敏感性分析纳入完全停用DMARD(N2),但未在主要网络中评估。
- 证据置信度对N4 vs N0为中等,对N3 vs N0为高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: International guidelines permit tapering disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) in sustained remission, but the de-escalation strategy with the lowest risk of flare remains unknown. Therefore, this study aimed to compare and rank flare risk across DMARD de-escalation strategies to guide more specific clinical decisions. METHODS: We performed a systematic review and a frequentist random-effects network meta-analysis (NMA) of clinical studies, evaluating DMARD tapering in adults with RA in remission (≥6 months). The primary network compared maintenance therapy (N0), simultaneous dose reduction of cDMARDs and bDMARDs (N1), discontinuation of bDMARDs while continuing cDMARDs (N3), and dose reduction of bDMARDs while continuing cDMARDs (N4). Flare risk was pooled as RR (95% CI) using a consistency model, with ranking by P-scores. Assessments of risk of bias, network inconsistency, and confidence in network estimates using CINeMA, as well as sensitivity analysis including complete DMARD withdrawal (N2), were also conducted. RESULTS: nineteen studies involving 3115 participants were included. Overall, tapering DMARDs increased the risk of flares compared with continued therapy (RR 1.94; 95%CI: 1.30-2.89). The primary NMA showed that tapering bDMARDs while continuing cDMARDs (N4) had the most favourable flare profile among the evaluated de-escalation strategies and was closest to maintenance therapy (RR 1.17; 95%CI: 0.76-1.82). In contrast, discontinuation of bDMARDs while continuing cDMARDs (N3) increased flare risk compared to N0 (RR 3.06; 95% CI: 1.81-5.16), and compared to N4 (RR 2.61; 95% CI: 1.44-4.72). The order of strategies identified was N0 > N4 > N1 > N3. CINeMA confidence was high for N3 versus N0 and moderate for N4 versus N0. CONCLUSIONS: Gradual bDMARD dose reduction while maintaining background cDMARD as backbone therapy showed the most favourable comparative flare profile, whereas bDMARD discontinuation was associated with a substantially higher flare risk.
引用
- Tandi YYP, Syafa'atulloh MY, Sigilipu YM, et al. Comparative efficacy and safety of disease-modifying antirheumatic drugs tapering strategies in sustained-remission rheumatoid arthritis: Systematic review and network meta-analysis. Semin Arthritis Rheum. 2026. PMID: 42843067. doi:10.1016/j.semarthrit.2026.153082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。